Os inibidores seletivos de recaptacão de serotonina no tratamento do transtorno do pânico: uma revisão sistemática de estudos placebo-controlados
DOI:
https://doi.org/10.25118/2763-9037.2012.v2.1013Palavras-chave:
serotonina, transtorno de pânicoResumo
Introdução: O transtorno do pânico (TP) é uma condição com alta prevalência na população e elevada morbidade. Os inibidores seletivos de receptação de serotonina (ISR$) são medicamentos vastamente utilizados na prática clínica para o tratamento deste transtorno. Objetivo: Realizar uma revisão sistemática atualizada dos estudos publicados que comparem de forma duplo-cega e randomizada o efeito dos ISRS versus o efeito placebo no TP e descrever o mecanismo de ação desta classe medicamentosa nos sintomas de ansiedade. Metodologia: A revisão sistemática foi realizada nas bases Medline/ PubMed" e “Web of Science - ISI”, utilizando como palavras-chave para busca os termos Mesh: panic disorder, placebo, fluoxetine, sertraline, paroxetine, citalopram, escitalopram e fluvoxamine. Resultados: Foram incluídos 11 estudos e todos demonstram a superioridade dos ISRS com relação ao placebo, apesar de ter sido constatado importante efeito placebo nos pacientes com TP. Conclusão: A ação inibitória da serotonina na panicogênese vem sendo confirmada por diversos estudos. Os ISRS são uma classe medicamentosa eficaz para o tratamento do TP e estudos placebo-controlados são importantes para esta avaliação. Não há evidência de eficácia diferencial entre as drogas desta classe. Estudos controlados de longo prazo ainda são necessários para avaliar os efeitos da continuidade destas medicações por períodos prolongados.
Downloads
Métricas
Referências
American Psychiatric Association. Practice Guideline for Treatment of Patients With Panic Disorder (Second Edition). American Psychiatric Publishing Inc, VA, USA (2009).
Kaspers, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur. Neuropsichopharmacol. 11, 307-321 (2001). DOI: https://doi.org/10.1016/S0924-977X(01)00100-6
Garakani H, Zitrin CM, Klein DF. Treatment of panic disorder with imipramine alone. Am. ). Psychiatry 141(3), 446-448 (1984). DOI: https://doi.org/10.1176/ajp.141.3.446
Mavissakalian M, Perel JM, Michelson L. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. ). Clin. Psychopharmacol. 4(1), 36-40 (1984). DOI: https://doi.org/10.1097/00004714-198402000-00006
Zitrin CM. Differential treatment of phobias: useof imipramine for panic attacks. ). Behav. Ther. Exp. Psychiatry 14(1), 11-18 (1983). DOI: https://doi.org/10.1016/0005-7916(83)90006-X
Cassano GB, Petracca A, Perugi G et al. Clomipraminee for panic disorder: |. The first 10 weeks of a long-term comparison with imipramine. ). Affect. Disord. 14(2), 123-127 (1988). DOI: https://doi.org/10.1016/0165-0327(88)90054-7
Lydiard RB, Morton WA, Emmanuel NP et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol. Bull. 29(2), 183-188 (1993).
Nardi AE, Nascimento |, Valença AM et al. Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricydlic antidepressant. Psychiatry Res. 120(3), 283-293 (2003). DOI: https://doi.org/10.1016/S0165-1781(03)00132-X
The American Psychiatric Publishing Textbook of Psychiatry (5th Edition). Hales RH, Yudofsky SC, Gabbard GN (Eds). American Psychiatric Publishing Inc, VA, USA (2008).
Zohar ), Westenberg HG. Anxiety disorders: a review of tricyclics antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatry Scand. Supl. 403, 39-49 (2000). DOI: https://doi.org/10.1111/j.1600-0447.2000.tb10947.x
Coplan JD, Pine DS, Papp LA, Gorman JM. An algorithm-oriented treatment approach for panic disorder. Psychiatr. Ann. 26, 192-201 (1996). DOI: https://doi.org/10.3928/0048-5713-19960401-09
Pollack MH, Smoller JW. Pharmacologic approaches to treatment-resistant panic disorder. In: Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies. Pollack MH, Otto MW, Rosenbaum JF (Eds). Guilford Press, NY, USA, 89-112 (1996).
Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. ). Affect. Disord. 51, 215-235 (1998). DOI: https://doi.org/10.1016/S0165-0327(98)00221-3
Maron E, Shlik ). Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 31,111 (2006). DOI: https://doi.org/10.1038/sj.npp.1300880
Kennett GA, Lightowler S, de Biasi V et al. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33(12), 1581-1588 (1994). DOI: https://doi.org/10.1016/0028-3908(94)90133-3
Yamauchi M, Tatebayashi T, Nagase K, Kojima M, Imanishi T. Chronic treatment with fluvoxamine desensitizes 5-HT2C. receptor-mediated hypolocomotion in rats. Pharmacol. Biochem. Behav. 78(4), 683-689 (2004). DOI: https://doi.org/10.1016/j.pbb.2004.05.003
Goddard AW, Sholomskas DE, Walton KE et al. Effects of tryptophan depletion in panic disorder. Biol. Psychiatry 36, 775-777 (1994). DOI: https://doi.org/10.1016/0006-3223(94)90091-4
Kent JM, Coplan JD, Martinez ), Karmally W, Papp LA, Gorman JM. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Psychiatry Res. 64, 83-90 (1996). DOI: https://doi.org/10.1016/0165-1781(96)02840-5
Gorman JM, Kent JM, Sullivan GM, Coplan JM. Neuroanatomical hypothesis of panic disorder, revised. Am). Psychiarry 157(4), 4933-505 (2000). DOI: https://doi.org/10.1176/appi.ajp.157.4.493
Maron E, Kuikka JT, Shlik ), Vasar V, Vanninen E, Tiihonen ). Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res. 132, 173-181 (2004). DOI: https://doi.org/10.1016/j.pscychresns.2003.10.004
Inoue T, Li XB, Abekawa T et al. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdale. Eur. ). Pharmacol. 497, 311-316 (2004). DOI: https://doi.org/10.1016/j.ejphar.2004.06.061
Michelson D, Lydiard RB, Pollack MH et al, Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am ). Psychiatry 155,1570-1577 (1998). DOI: https://doi.org/10.1176/ajp.155.11.1570
Londborg PD, Wolkow R, Smith WT etal. Sertraline in the treatment of panic disorder: a multi-site, double- blind, placebo-controlled, fixed-dose investigation. Br.). Psychiatry 173(7), 54-60 (1998). DOI: https://doi.org/10.1192/bjp.173.1.54
Pollack, MH, Otto MW, Worthington )J, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch. Gen. Psychiarry 55, 1010-1016 (1998). DOI: https://doi.org/10.1001/archpsyc.55.11.1010
Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am ). Psychiatry 155, 1189-1195 (1998). DOI: https://doi.org/10.1176/ajp.155.9.1189
Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am ). Psychiatry 155, 36-42 (1998). DOI: https://doi.org/10.1176/ajp.155.1.36
Lecrubier Y, Bakker A, Dunbar G, Judge R; the Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr. Scand. 95. 145-152 (1997). DOI: https://doi.org/10.1111/j.1600-0447.1997.tb00388.x
Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194, 233-242 (2007). DOI: https://doi.org/10.1007/s00213-007-0821-0
Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the trearment of panic disorder. ). Clin. Psychiatry 66, 34-40 (2005). DOI: https://doi.org/10.4088/JCP.v66n0105
Stahl SM, Gergel |, Li D. Escitalopram in the trearment of panic disorder: a double-blind, randomized, placebo-controlled trial. ). Clin. Psychiatry 64, 1322-1327 (2003). DOI: https://doi.org/10.4088/JCP.v64n1107
Nair NPY, Bakish D, Saxena B, Amin M, Schwartz G, West TEG. Comparison of luvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder. Anxiety 2, 192-198 (1996). DOI: https://doi.org/10.1002/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q
Asnis GM, Hameedia FA, Goddardb AW et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 103, 114 (2001). DOI: https://doi.org/10.1016/S0165-1781(01)00265-7
Smit F, Willemse G, Meulenbeek P et al. Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial. Cost Eff. Resour. Alloc. 7, 8 (2009). DOI: https://doi.org/10.1186/1478-7547-7-8
Sheehan DV, Harnett-Sheehan K. The role of SSRis in panic disorder. ). Clin. Psychiatry 57(Suppl) 10, 51-58; discussion 59-60 (1996).
Hirschfeld RM. Placebo response in the treatment of panic disorder. Bull. Menninger Clin. 60(2 Suppl. A), AT6-AB6 (1996).
Huppert JD, Schultz LT, Foa EB et al. Differential response to placebo among. patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am.). Psychiatry 161, 1485-1487 (2004). DOI: https://doi.org/10.1176/appi.ajp.161.8.1485
Piercy MA, Sramek )), Kurtz NM, Cutler NR. Placebo response in anxiety disorders. Ann. Pharmacother. 30(9), 1013-1019 (1996). DOI: https://doi.org/10.1177/106002809603000917
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2012 Marina Dyskant Mochocovitch, Antonio Egidio Nardi
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
